LUPIN vs WINDLAS: Stock Comparison

Lupin Limited vs Windlas Biotech Ltd

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Lupin Limited is the larger company by market capitalisation. Lupin Limited shows a lower P/E, a higher ROE and faster revenue growth, while Windlas Biotech Ltd shows a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lupin Limited and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LUPIN is more favourable on 10 of 13 scored metrics and WINDLAS on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
LUPIN is the larger company
₹1.08 L Cr vs ₹1,775 Cr
P/E Ratio
LUPIN has a lower P/E
20.35x vs 27.23x
P/B Ratio
WINDLAS has a lower P/B
3.12x vs 4.83x
EPS
LUPIN has higher earnings per share
₹116.56 vs ₹31.5
Dividend Yield
WINDLAS has a higher dividend yield
0.73% vs 0.48%
Revenue Growth (TTM YoY)
LUPIN has faster revenue growth
31.9% vs 17.7%
EPS Growth (TTM YoY)
LUPIN has faster EPS growth
89% vs -2.6%
Qtr Sales Growth
LUPIN has stronger quarterly sales growth
31.9% vs 17.7%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLUPINWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLUPINWINDLAS
Live Price₹2,370.5₹857.95
Day Change-1.08%-0.41%
Volume7.26 L31,663
52-Week High₹2,529.5₹1,097.9
52-Week Low₹1,836.8₹697.4
Distance from 52W High-6.29%-21.86%

Valuation

MetricLUPINWINDLAS
Market Cap₹1.08 L Cr₹1,775 Cr
P/E Ratio20.35x27.23x
P/B Ratio4.83x3.12x
EPS₹116.56₹31.5
Book Value₹491.29₹275
Dividend Yield0.48%0.73%

Growth

MetricLUPINWINDLAS
Revenue Growth (TTM YoY)31.9%17.7%
EPS Growth (TTM YoY)89%-2.6%
Qtr Sales Growth31.9%17.7%
Qtr Profit Growth101%-1.78%

Profitability & Leverage

MetricLUPINWINDLAS
ROE29.1%12.2%
ROCE30.3%15.9%
Net Margin17.65%7.35%
Operating Margin31.5%11.6%
Debt to Equity0.29x0.06x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricLUPINWINDLAS
Promoter Holding46.57%63.31% 1.41 pp
FII Holding22.42% 0.71 pp2.04% 1.44 pp
DII Holding24.65% 0.67 pp9.84% 1.97 pp
Public Holding6.08% 0.03 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lupin Limited and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.